Lexicon Pharmaceuticals Shares Drop 10% After Trial Results for LX9211
June 30 2022 - 11:07AM
Dow Jones News
By Chris Wack
Lexicon Pharmaceuticals Inc. shares fell 10% to $2.01 after the
company reported top-line results of its Phase 2 proof-of-concept
study of LX9211 in painful diabetic neuropathy.
The company said LX9211 achieved the primary endpoint of the
study, demonstrating a statistically significant reduction in the
average daily pain score. Some adverse events were reported at the
higher dose, including dizziness, headache and nausea. Nearly all
adverse events were reported as mild or moderate.
There were no drug-related serious adverse events reported in
the study.
LX9211 is an orally delivered, selective small molecule
inhibitor of AAK1, which preclinical studies have shown to reduce
pain behavior in models of neuropathic pain without affecting
opiate pathways.
LX9211 has received fast track designation from the U.S. Food
and Drug Administration for the development in diabetic peripheral
neuropathic pain.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 30, 2022 10:52 ET (14:52 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024